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Purpose: Tumor hypoxia, often found in nonsmall cell lung cancer (NSCLC), implies an increased
resistance to radiotherapy. Pretreatment assessment of tumor oxygenation is, therefore, warranted in
these patients, as functional imaging of hypoxia could be used as a basis for dose painting. This study
aimed at investigating the feasibility of using a method for calculating the dose required in hypoxic
subvolumes segmented on 18F-HX4 positron emission tomography (PET) imaging of NSCLC.
Methods: Positron emission tomography imaging data based on the hypoxia tracer 18F-HX4 of 19
NSCLC patients were included in the study. Normalized tracer uptake was converted to oxygen par-
tial pressure (pO2) and hypoxic target volumes (HTVs) were segmented using a threshold of
10 mmHg. Uniform doses required to overcome the hypoxic resistance in the target volumes were
calculated based on a previously proposed method taking into account the effect of interfraction
reoxygenation, for fractionation schedules ranging from extremely hypofractionated stereotactic body
radiotherapy (SBRT) to conventionally fractionated radiotherapy.
Results: Gross target volumes ranged between 6.2 and 859.6 cm3, and the hypoxic fraction
< 10 mmHg between 1.2% and 72.4%. The calculated doses for overcoming the resistance of cells in
the HTVs were comparable to those currently prescribed in clinical practice as well as those previ-
ously tested in feasibility studies on dose escalation in NSCLC. Depending on the size of the HTV
and the distribution of pO2, HTV doses were calculated as 43.6–48.4 Gy for a three-fraction sched-
ule, 51.7–57.6 Gy for five fractions, and 59.5–66.4 Gy for eight fractions. For patients in whom the
HTV pO2 distribution was more favorable, a lower dose was required despite a bigger volume. Tumor
control probability was lower for single-fraction schedules, while higher levels of tumor control prob-
ability were found for schedules employing several fractions.
Conclusions: The method to account for heterogeneous and dynamic hypoxia in target volume seg-
mentation and dose prescription based on 18F-HX4-PET imaging appears feasible in NSCLC
patients. The distribution of oxygen partial pressure within HTV could impact the required prescribed
dose more than the size of the volume. © 2019 American Association of Physicists in Medicine
[https://doi.org/10.1002/mp.13514]
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1. INTRODUCTION
The field of radiotherapy is rapidly evolving with respect to
physics, biology, and technology. While the technical devel-
opment has allowed for the exploration of highly advanced
treatments with increasing biological effectiveness,1
research has also been focused on ways of increasing the
efficiency of routine treatment techniques by targeting the
tumor microenvironment.2 As the therapeutic portfolio is
continuously growing, the ability to consider and evaluate
key radiobiological processes that are likely to govern the
outcome of a treatment becomes increasingly important.
Thus, in order to truly advance the practice of radiotherapy,
crucial characteristics of the tumor microenvironment in
conjunction with the treatment regimen need to be carefully
studied.
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One of the most important features of the tumor microen-
vironment with respect to radioresistance is hypoxia, since
the isoeffective dose in hypoxic conditions could be up to
three times higher than in normoxic conditions as quantified
by the oxygen enhancement ratio.3 Poor oxygenation has
been well established to substantially increase the radioresis-
tance of tumors and impact negatively on the outcome of
radiotherapy.4 In spite of this, there is currently no generally
accepted approach for hypoxia mitigation in radiotherapy,
and pretreatment imaging of hypoxia is part of the clinical
routine only in very few centers around the world.5 However,
several advanced therapeutic approaches to overcome the
issue of hypoxia have been investigated, including dose paint-
ing. One tumor type in which dose painting has been fre-
quently investigated is nonsmall cell lung cancer (NSCLC).
In general, lung cancer has poor prognosis and convention-
ally fractionated radiotherapy has been found to be inefficient
in achieving local control in these patients.6 In pursuit of an
alternative treatment strategy with increased biological effec-
tiveness, stereotactic body radiotherapy (SBRT) has been
successfully applied to treat NSCLC with the majority of
schedules ranging from one to ten fractions.7–9 However, a
high prevalence of hypoxia that varies dramatically in degrees
between patients has been observed in NSCLC in particular.10
Furthermore, studies investigating the evolution of hypoxia in
these tumors over time have also shown that the tumor
microenvironment is far from static in NSCLC patients,11 and
the importance of taking into account a heterogeneous and
dynamic tumor oxygenation in SBRT of NSCLC has been
previously demonstrated.12
In light of the dynamic nature of tumor oxygenation,13 the
challenges in radiotherapy of lung cancer driving the treat-
ments to extreme hypofractionation warrant a robust method
of evaluating the impact of fractionation on the outcome of
these treatments with respect to tumor hypoxia, in particular.
This is of high relevance for identifying SBRT fractionation
schedules that could be preferred to others from the point of
view of hypoxia and interfraction reoxygenation. It was the
purpose of this study to investigate the impact of fractionation
in hypoxia dose painting in NSCLC, based on the conversion
of tracer uptake of a novel hypoxia positron emission tomogra-
phy (PET) tracer, 18F-HX4, to oxygen partial pressure.
2. MATERIALS AND METHODS
A previously developed function for converting normal-
ized tracer uptake to oxygen partial pressure (pO2) was
applied to HX4-PET imaging data of 19 NSCLC patients.
The expression for performing this conversion was originally
derived based on experimental measurements of the normal-
ized tracer uptake and the oxygen partial pressure pO2.
14,15
This expression relates the normalized uptake, Uptakenorm,i,
in each voxel i to the pO2,i in that voxel as:
Uptakenorm;i ¼ A B  pO2;iC þ pO2;i (1)
where A, B, and C are tracer-specific parameters that have
been derived for 18F-HX4 as A = 10.9, B = 10.7, and
C = 0.1.16 The first step is thus to normalize the uptake to
obtain Uptakenorm,i. In each individual patient, a reference
volume that contains normal, well-oxygenated tissue is delin-
eated. The average value of the PET signal intensity in this
volume is calculated and assumed to correspond to
60 mmHg, an oxygen partial pressure that could be expected
in normoxic tissues17:
Uptakeref ¼ A B  60C þ 60 (2)
All uptake values are normalized by Uptakeref and Eq. (1)
is subsequently used to perform the conversion to pO2. In the
present paper, the aortic arch was considered as the reference
volume in accordance with previous studies on hypoxia dose
painting based on 18F-HX4.18,19 The resulting three-dimen-
sional, heterogeneous distribution of pO2 for each patient can
be used for segmentation of target volumes as well as for
quantifying the hypoxia-induced radioresistance of the tumor
for dose painting purposes. In this way, hypoxic target vol-
umes (HTV) were segmented in each of the 19 patients based
on a pO2 threshold of 10 mmHg. This value is in the upper
limit of what is conventionally considered for the hypoxic
threshold (i.e., 2.5–10 mmHg20) and could, therefore, be con-
sidered the safest approach with respect to ensuring the inclu-
sion of the clinically relevant hypoxia in the hypoxic target
volume. The segmented volumes were considered in relation
to the clinical gross target volume (GTV).16,19 If the HTV
partly extended outside of the GTV, the GTV was adjusted to
include the HTV in accordance with the expected course of
action in a similar situation in the clinic. In some cases, this
also inferred adjusting the clinical target volume (CTV) to
encompass the new GTV. Subsequently, the HTV was con-
sidered a target for hypoxia-based dose painting, and the pre-
scribed uniform dose required for 95% tumor control
probability was calculated according to the method proposed
by Toma-Dasu et al.14 In this method, the conversion of nor-
malized uptake to oxygen partial pressure is followed by the
calculation of a voxelized map of dose-modifying factors
(DMFs).14,15,21 The probability of tumor clonogenic cell sur-
vival in each voxel is then calculated based on a radiobiologi-
cal model of cell survival such as the linear-quadratic (LQ)
model, in which the radiosensitivity parameters a and b are
modified according to the DMFs. Conversely, a desired level
of cell survival or, rather, tumor control probability can be
assumed, and the dose D̂ðrÞ required in each voxel at position
r to achieve this probability (P) can be calculated as:
D̂ðrÞ ¼ n aðrÞ
2bðrÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 1
n
4bðrÞ
a2ðrÞ lnð
Vq
 lnPÞ
s
 1
" #
(3)
where a(r) and b(r) are the linear-quadratic radiosensitivity
parameters, modified to depend on the pO2, n is the number
of fractions, and q is the density of clonogenic cells in the
whole tumor volume V.14,15 Depending on the distribution of
pO2 in the volume, Eq. (3) could result in a highly
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heterogeneous dose distribution that will be successful in
controlling the tumor only if (a), the dose distribution is phys-
ically and technically feasible to deliver with high accuracy
under the clinically accepted constraints for the normal tissue
and the organs at risk, and (b), the tumor oxygenation
remains exactly the same as represented in the original PET
image. While the former is debatable, the tumor oxygenation
is certainly expected to change between the time point of
imaging and the treatment due to fluctuations in acute hypox-
ia.13 This is equally well expected to occur between fractions
throughout the treatment, warranting the inclusion of this
effect in the calculation of the dose to be delivered. Under the
conservative assumption that no global improvement is to be
expected, the local changes in the tumor oxygenation will not
affect the average pO2 or, correspondingly, the average
radiosensitivity. Thus, the random variations in acute hypoxia
could be considered to correspond to a variance around the
average radiosensitivity. Consequently, an average dose D
with a variance r2D corresponding to the heterogenous dose
distribution can be calculated. Based on a desired level of
tumor control probability (P), a homogeneous prescribed
dose Dpres can then be calculated as:
Dpres ¼
D
1 c2PðDÞ ðrDD Þ2
h i (4)
where c is the normalized slope of the dose–response curve
corresponding to a homogeneous irradiation. While the
resulting dose prescription is uniform, the heterogeneity in
pO2 on voxel level within the HTV is hence taken into
account.14,15 To ensure local control, the whole CTV has to
be considered. The method for calculating the prescribed
dose to the HTV was, therefore, applied also to the gross
tumor volume (GTV) excluding the HTV, and the CTV
excluding the GTV, respectively (Fig. 1). By segmenting the
tumor in this way, the uniform dose prescription can be per-
formed for individual subvolumes each with a more homoge-
neous radiosensitivity than in the whole tumor volume.
By varying the number of fractions, n, in Eq. (3), a range
of fractionation schedules was considered in the present
study. Given the increasing use of SBRT and failure of con-
ventionally fractionated schedules in NSCLC, the analysis
was focused on schedules employing between 1, 3, 5, 8, and
10 fractions. For comparison with the results of Even and col-
leagues,18 n = 24 fractions were also considered, as well as a
conventionally fractionated treatment of 30 fractions. For the
purposes of the current study, calculations were performed
for all fractionation schedules for each tumor regardless of
the tumor volume and location.
Equation (4) was initially introduced under the assump-
tion of several changes in radiosensitivity of the cells due to
local interfractional fluctuations of acute hypoxia. Its validity
could thus be questioned for hypofractionated treatments.
The calculated prescribed doses were, therefore, evaluated
with respect to the level of control they would ensure for dif-
ferent fractionation schedules by calculating the tumor con-
trol probability (TCP) in each target volume V divided into N
voxels containing the same number of cells Nvox as:
TCP ¼
YN
i¼1
expðNvoxSFiÞ (5)
where SFi is the surviving fraction in voxel i given by:
SFi ¼
Yn
k¼1
exp  1
n
a
DMFi;k
Dpres þ bDMF2i;k
D2pres
n
 !" #
(6)
with DMFi,k corresponding to the pO2-dependent dose-
modifying factor in voxel i and fraction k,21 a and b to the lin-
ear-quadratic model parameters for the corresponding pO2
conditions, and n to the number of fractions. To include the
effects of interfraction reoxygenation in the calculation of
TCP for the schedules employing more than one fraction, the
DMFi,k in Eq. (6) were randomly resampled from the three-
dimensional distribution mimicking the fluctuations in
radiosensitivity related to changes in acute hypoxia. As a con-
servative approach with respect to achieving local control, no
global improvement in the tumor oxygenation was assumed.
For all calculations, a uniform density of clonogenic cells
of 109 cm3 was assumed in all target volumes. The numeri-
cal values of the generic parameters used in Eqs. (3) and (4)
were a = 0.35 Gy1, a/b = 10 Gy, c = 4.22,23
3. RESULTS
For the patients included in this study, the GTVs ranged
between 6.2 and 859.6 cm3, with an average and median size
of 150.8 and 101.7 cm3, respectively. In Fig. 1, the target vol-
umes considered for dose painting are illustrated, and in
Fig. 2, examples of the segmented HTVs are shown for four
of the patients. While a single HTV was observed in several
of the patients as illustrated in Fig. 1, there were also cases in
which several volumes with pO2 < 10 mmHg were found.
Regardless of the spatial distribution of voxels < 10 mmHg,
the total HTV volume in each patient was considered for the
calculation of the prescribed doses. As previously mentioned,
the GTV was adjusted to fully encompass the HTV contained
FIG. 1. Illustration of the target volumes considered for homogeneous dose
prescription: clinical target volume (CTV), gross target volume (GTV),
hypoxic target volume (HTV), the GTV not containing the HTV (GTV-
HTV), and the CTV not containing the GTV (CTV-GTV). [Color figure can
be viewed at wileyonlinelibrary.com]
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in the planning target volume (PTV). In a majority of the
patients (11/19), the adjusted GTV was <1% larger than the
original GTV, and in only 5 of 19 patients, the adjusted GTV
was more than 1% but less than 5% larger than the originally
delineated volume. The largest change of 74% was observed
in patient 7. This patient had the smallest GTV in the entire
cohort of only 6.2 cm3, which was adjusted to 10.7 cm3 to
encompass the 7.8 cm3 HTV.
Table I shows the uniform prescribed dose to the HTV,
the GTV-HTV, and the CTV-GTV for the 19 patients
included in the study for the range of fractionation schedules
considered. Patient 1 was excluded due to the negligible
hypoxic target volume of 0.1 cm3. For all evaluated patients
(patients 2–19) with HTVs of 0.8–84.5 cm3, the HTV dose
was consistently higher than both the GTV-HTV and the
CTV-GTV doses. This could indicate that segmentation
based on hypoxia PET imaging is warranted, especially for
cases in which the size of the HTV and the pO2 distribution
result in a required prescribed dose that is substantially higher
than what is needed in the remainder of the GTV and the
CTV. In patient 14, for example, the HTV dose for a five-
fraction treatment is more than 12 Gy higher than the dose to
the CTV-GTV (56.9 and 44.3 Gy, respectively), comparable
to one fraction in a typical five-fraction SBRT treatment.9
The need for segmentation could be further demonstrated by
considering the results for a more conventional approach in
which the treatment consists of 30 fractions. For such a
schedule, the total doses calculated correspond to a fractional
dose of 2.8 Gy or higher in 13 of the 18 evaluated patients.
While this is a dose that would most likely be feasible to deli-
ver to a tumor subvolume such as an HTV,24,25 it could be
challenging to deliver as a uniform dose to the entire PTV
within the limits of normal tissue toxicity constraints.
Interestingly, although the HTV is nearly identical in abso-
lute size in patients 14 and 15, a higher dose is required in
patient 14. This can be explained by considering the
distribution of oxygen partial pressure within the HTVs,
shown in Fig. 3 for patients 2–19 (in patient 1, the HTV is
virtually zero). Indeed, in patient 14 the histogram displays a
pO2 distribution that is shifted toward lower values compared
with patient 15, a difference that is reflected in the calculated
dose. In fact, the prescribed dose for patient 14 is even higher
than for patient 19, in which the largest HTVof 84.5 cm3 was
found, (to be compared with a volume of 61.1 cm3 in patient
14). Thus, considering the distribution of oxygen partial pres-
sure within the segmented HTV as opposed to just the size of
the volume could lead to a difference in the subsequent dose
prescriptions that might ultimately reflect on the treatment
outcome.
Table II shows the TCP in the HTV for the prescribed
doses in Table I. For all multifraction schedules, a TCP
higher than the specified TCP of 95% is achieved. For the
single-fraction schedule, a TCP of only 87.6% and 88.7% is
obtained in patients 12 and 14, respectively. In these
patients, the least favorable oxygen partial pressure distribu-
tions were found (Fig. 3), indicating the importance of con-
sidering not only the size of the HTV but also the
distribution of pO2. For three fractions, the TCP increases
for all patients, with the largest increase seen in patients 12
and 14 from 87.6% to 98.2% in patient 12, and from 88.7%
to 97.0% in patient 14. This could indicate that fractionated
rather than single-fraction SBRT is preferable in tumors with
unfavorable pO2 distributions.
4. DISCUSSION
The potential for improving the outcome of radiotherapy
by using functional imaging to identify and subsequently tar-
get tumor subvolumes believed to contain more radioresistant
cells was first proposed almost two decades ago by Ling and
colleagues.26 Since then, various strategies to perform dose
painting have been proposed ranging from dose painting by
FIG. 2. Examples of segmented hypoxic target volumes (yellow) in the gross target volume (blue), as well as the clinical target volume (purple) and planning
target volume (red) in four of the patients. The estimated hypoxic fraction (HF) in each case is indicated in the panels. [Color figure can be viewed at wileyonline
library.com]
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TABLE I. The uniform prescribed dose for 95% tumor control probability to the hypoxic target volumes (HTV), gross target volume (GTV)-HTV, and the clinical
target volume (CTV)-GTV for patients 2–19 assuming a treatment consisting of 1, 3, 5, 10, 24, or 30 fractions and a uniform clonogen density of 109 cm3.
Patients are ordered according to the physical size of the HTV.
Patient
Target
volume
Volume
(cm3; % of GTV)
Dpres (Gy)
1 fraction 3 fractions 5 fractions 8 fractions 10 fractions 24 fractions 30 fractions
2 HTV 0.8 (1.6) 28.7 44.0 52.3 60.3 64.1 77.7 80.7
GTV-HTV 49.8 25.8 39.6 47.1 50.6 57.7 70.0 67.2
CTV-GTV 55.9 24.3 37.1 44.0 54.3 53.7 64.8 72.7
3 HTV 1.4 (1.2) 29.3 45.1 53.7 61.9 65.8 80.1 83.2
GTV-HTV 112.5 26.0 40.0 47.6 51.4 58.4 71.1 68.5
CTV-GTV 151.6 24.6 37.6 44.7 55.0 54.6 66.0 73.8
4 HTV 2.9 (1.9) 29.2 44.8 53.4 61.6 65.5 79.6 82.7
GTV-HTV 146.1 26.2 40.3 47.9 51.6 58.8 71.5 68.8
CTV-GTV 89.9 24.7 37.8 44.9 55.3 54.8 66.3 74.3
5 HTV 4.4 (38.9) 29.2 44.7 53.1 61.1 64.8 78.4 81.3
GTV-HTV 6.9 26.0 39.8 47.2 49.3 57.7 69.7 65.1
CTV-GTV 17.5 23.8 36.3 43.0 54.3 52.3 62.9 72.3
6 HTV 5.8 (13.8) 29.0 44.4 52.8 60.8 64.6 78.4 81.4
GTV-HTV 36.0 26.0 39.9 47.4 50.0 58.1 70.4 66.4
CTV-GTV 43.8 24.0 36.7 43.5 54.7 53.1 64.0 73.1
7 HTV 7.8 (72.4) 28.5 43.5 51.7 59.5 63.2 76.3 79.1
GTV-HTV 3.0 26.8 41.0 48.7 51.1 59.4 71.8 67.4
CTV-GTV 11.9 24.7 37.6 44.5 56.0 54.1 65.0 74.5
8 HTV 11.1 (17.9) 29.8 45.8 54.5 62.8 66.7 81.0 84.1
GTV-HTV 51.1 26.6 40.7 48.5 51.6 59.4 72.1 68.5
CTV-GTV 66.6 24.7 37.8 44.8 55.9 54.7 66.1 74.8
9 HTV 11.2 (34.3) 29.5 45.2 53.8 61.9 65.8 79.7 82.7
GTV-HTV 21.5 26.1 40.0 47.6 50.4 58.2 70.5 66.8
CTV-GTV 34.2 24.2 37.0 43.9 54.8 53.5 64.4 73.2
10 HTV 12.1 (26.3) 29.3 44.9 53.4 61.5 65.4 79.3 82.3
GTV-HTV 33.8 26.3 40.4 48.0 50.8 58.8 71.3 67.4
CTV-GTV 56.8 24.4 37.2 44.2 55.3 53.9 65.0 74.1
11 HTV 36.8 (24.8) 30.1 46.1 55.0 63.4 67.4 82.0 85.2
GTV-HTV 111.2 26.6 40.9 48.7 51.7 59.8 72.6 69.0
CTV-GTV 101.1 24.7 37.8 45.0 56.2 55.0 66.5 75.5
12 HTV 44.8 (43.1) 31.5 48.4 57.6 66.4 70.6 85.8 89.1
GTV-HTV 59.0 26.1 40.1 47.7 51.2 58.5 71.1 68.2
CTV-GTV 78.4 24.5 37.5 44.5 55.1 54.4 65.7 73.8
13 HTV 47.3 (39.7) 30.4 46.7 55.6 64.1 68.2 82.8 86.0
GTV-HTV 71.7 26.8 41.2 49.0 51.4 60.1 73.0 68.4
CTV-GTV 80.8 24.6 37.6 44.6 56.5 54.5 65.9 75.8
14 HTV 61.1 (66.0) 31.2 47.8 56.9 65.6 69.8 84.7 87.9
GTV-HTV 31.4 26.5 40.6 48.3 50.9 59.2 71.8 67.7
CTV-GTV 47.2 24.4 37.3 44.3 55.7 54.0 65.2 74.6
15 HTV 62.2 (36.8) 30.2 46.5 55.3 63.8 67.9 82.6 85.8
GTV-HTV 106.7 27.0 41.5 49.4 52.4 60.6 73.7 69.8
CTV-GTV 105.2 25.0 38.3 45.5 57.0 55.6 67.3 76.5
16 HTV 63.2 (7.4) 31.0 47.8 57.0 65.9 70.1 85.6 89.0
GTV-HTV 796.8 26.9 41.4 49.3 53.3 60.7 74.1 71.5
CTV-GTV 259.8 25.3 38.8 46.2 57.0 56.7 68.8 77.0
17 HTV 63.4 (16.9) 30.5 47.0 56.0 64.7 68.8 83.9 87.2
GTV-HTV 312.2 27.2 41.8 49.9 53.1 61.3 74.7 71.1
CTV-GTV 281.5 25.3 38.8 46.1 57.6 56.5 68.5 77.6
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numbers (DPBN), in which the dose distribution is allowed
to be highly heterogeneous, to dose painting by contours
(DPBC), in which larger volumes are prescribed a uniformly
escalated dose.27 DPBN could be questioned both from the
point of view of the physical and technical limitations in
delivering highly heterogeneous dose distributions, as well as
the sensitivity of such a distribution to potential temporal
changes in the microenvironment that cannot be resolved in a
PET image. DPBC could thus provide a superior alternative
with respect to both feasibility and robustness, and hence
treatment outcome.14,28 In NSCLC, several studies have
investigated dose painting based on different tracers such as
18F-labeled flurorodeoxyglucose (FDG), fluoromisonidazole
(FMISO), and flortanidazole (HX4).18,29 Furthermore, sev-
eral modeling studies investigated the influence of heteroge-
neous tumor hypoxia on the treatment outcome.21,30–33
However, given the qualitative information obtained from
PET imaging, the determination of the prescribed dose still
presents a challenge to the concept of dose painting in gen-
eral. While the relationship between increased tumor metabo-
lism, as reflected by FDG uptake, and radiosensitivity has
not been elucidated, the relationship between oxygen partial
pressure and relative radioresistance can be described mathe-
matically. The method proposed by Toma-Dasu et al.14,15,
and used in this work, is based on this relationship.
By converting the normalized tracer uptake to pO2, sub-
volumes can be delineated based on a hypoxic rather than an
uptake threshold, and the dose that is required in order to
overcome the resistance resulting from the pO2 distribution
within that volume can be calculated.14,15 It has to be men-
tioned, however, that the mathematical expression in Eq. (4)
used to calculate the homogeneous dose to be prescribed
starting from a heterogeneous dose calculated at voxel level
has a generic character and it depends on the standard devia-
tion of these dose values. The heterogeneous dose distribu-
tion could be related to heterogeneous radiosensitivity of the
cells in different voxels due to multiple reasons, one of them
being the spatially heterogeneous oxygenation, but not exclu-
sively. The expression for calculating the prescribed homoge-
neous dose, therefore, includes the standard deviation of the
heterogeneous dose because of variations in radiosensitivity
that could have many underlaying causes. Given the general
character of the mathematical expression, one could say that
the prescription dose is based on variations in radiosensitivity
within a given interval. In this study, the definition of this
interval was based on the hypothesis that the dominant factor
leading to a variation in radiosensitivity is acute hypoxia.
Thus, the prescribed homogeneous dose will ensure the tar-
geted control probability as long as the spatial and temporal
variations in radiosensitivity are within the given interval,
regardless of the underlying causes. As can be seen in
Eq. (4), the resulting uniform prescribed dose is always larger
than the average dose required based on the pO2 distribution.
This can be explained by the fact that in a volume with
heterogeneous sensitivity, the average dose required will cor-
respond to underdosing the more resistant areas that cannot
be compensated by overdosing the sensitive areas.22 While
this is also true for the prescribed dose (which will not corre-
spond to the maximum dose required either), the random
fluctuations in acute hypoxia expected to occur between frac-
tions13 will cause the “effective” radiosensitivity distribution
— and consequently, the corresponding dose distribution —
to become narrower. A narrow distribution of the radiosensi-
tivity can also be expected in the better oxygenated remainder
of the target volume (GTV-HTV, and CTV-GTV), in which
the dose is calculated separately using the proposed method.
In addition to the benefit in considering subvolumes with
similar radiosensitivity as opposed to the whole tumor, the
results of this work indicate the importance of considering
the distribution of pO2 within the HTV. This is demonstrated
by a higher total dose required for a volume with a less favor-
able oxygen partial pressure distribution than in larger vol-
umes with generally higher pO2.
In light of the previous work on hypoxia dose painting by
Even and colleagues,18 the uniform prescribed doses calcu-
lated in this work could be considered clinically feasible with
respect to the normal tissue toxicity constraints. Furthermore,
the calculated doses corresponding to typical SBRT fraction-
ation schedules (i.e., 1–10 fractions) are comparable to what
is prescribed in the clinic. For example, in patients 12–19
with the largest HTVs of 44.8 to 84.5 cm3, the prescribed
doses were calculated as 46.3–48.4 Gy for three fractions,
55.2–57.6 Gy for five fractions, and 63.8–66.4 Gy for eight
fractions. These results could be compared with the work of
Baumann et al.8 prescribing 45 Gy in three fractions to the
67% isodose and achieving local control rates exceeding
90%. Similarly, Haasbeek et al.9 prescribed 60 Gy in eight
fractions to the 80% isodose and observed a 3-yr local control
TABLE I. Continued.
Patient
Target
volume
Volume
(cm3; % of GTV)
Dpres (Gy)
1 fraction 3 fractions 5 fractions 8 fractions 10 fractions 24 fractions 30 fractions
18 HTV 80.6 (27.3) 30.2 46.3 55.2 63.8 67.8 82.6 85.8
GTV-HTV 214.3 27.2 41.8 49.8 52.3 61.2 74.5 69.9
CTV-GTV 132.6 25.0 38.2 45.4 57.5 55.6 67.4 77.4
19 HTV 84.5 (39.5) 30.6 47.0 55.9 64.6 68.7 83.6 86.9
GTV-HTV 129.7 26.9 41.4 49.3 52.1 60.5 73.6 69.6
CTV-GTV 142.9 24.9 38.1 45.3 56.9 55.4 67.1 76.5
Medical Physics, 46 (5), May 2019
2517 Kjellsson Lindblom et al.: Fractionation in hypoxia dose painting 2517
FIG. 3. Oxygen partial pressure histograms in the hypoxic target volume (HTV) for patients 2–19 (the histogram for patient 1 was excluded from this figure due
to the negligible size of the HTV).
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of 89%. The agreement between the clinically prescribed
SBRT doses resulting in high levels of local control and the
prescribed doses for 95% tumor control probability calcu-
lated here could contribute to the explanation of the success
of SBRT in NSCLC even in presumably rather hypoxic
tumors. As the prescription isodoses clinically employed
could vary substantially, different outcomes of the treatments
depending on the resulting dose distribution in relation to the
microenvironment of the tumor could be expected. For exam-
ple, with the dose prescription of 7.5 Gy 9 8 to the isocenter
with a PTV-encompassing isodose of at least 90% reported
by Shirata et al.34, parts of the tumor could receive only
54 Gy in eight fractions, which is several Gy below the HTV
doses calculated in the present work for a treatment consist-
ing of eight fractions. As it is not safe to assume that hypoxic
regions are located in the center of the tumor where the high-
est doses would be delivered in SBRT,35 the need for compre-
hensive pretreatment assessment of the tumor oxygenation in
SBRT is further highlighted.
The details of the tumor oxygenation and its evolution
throughout the treatment could also greatly impact on the
treatment outcome. In NSCLC, conventional fractionation
has failed to achieve satisfying levels of local control6 while
impressive results have instead been obtained with SBRT,
even resulting in surgery as primary treatment strategy in
these patients being challenged.36,37 The striking outcome
achieved with SBRT has fostered the pursuit for an optimal
radiotherapy treatment approach in NSCLC in particular, as
has been recently reviewed by Ruggieri et al.38 In this
respect, efforts have been focused on both tumor control and
normal tissue toxicity, and considering both the dose and the
fractionation.39–41 In a modeling study simulating the SBRT
treatment of hypoxic NSCLC tumors, the impact of interfrac-
tion reoxygenation was shown to result in almost identical
isoeffective total doses for a three- and a five-fraction sched-
ule.12 This is in line with the work by Park and colleagues,
showing a similar overall survival in 5600 NSCLC patients
treated with either a three-, four-, or five-fraction SBRT.42
While Ma and colleagues found no difference in clinical out-
come in NSCLC patients treated with either a single- or
three-fraction SBRT,43 Huang et al.44 concluded that a single
fraction of 30 Gy was superior to 12 Gy 9 4. However, in
the modeling study by Huang and coworkers, the impact of
tumor reoxygenation was not included as in the study by
Lindblom et al. In addition, Huang et al. only included clini-
cal data on NSCLC tumors of very limited size (<3 cm) in
order to exclude the impact of tumor size. Their conclusions
could thus be limited to small, well-oxygenated tumors. In
addition to the expected benefit in local control from inter-
fraction reoxygenation in fractionated as opposed to single-
fraction SBRT, Jain et al.40 compared the acute toxicity and
quality of life in NSCLC patients treated with SBRT in either
4 or 11 days and found that patients treated for the longer per-
iod of 11 days fared better. In general, the collected work on
the impact of treatment time, dose and fractionation in SBRT
of NSCLC indicate that finding the optimal radiotherapy
treatment strategy requires a multifaceted approach in which
the most crucial aspects impacting on the overall outcome
have to be taken into account. In the present study, the tumor
control probability evaluated as described by Eqs. (5) and (6)
indicate that fractionated rather than single-fraction SBRT
treatments should be considered in order to maximize the
TABLE II. The uniform prescribed dose for 95% tumor control probability to the hypoxic target volumes (HTV) and the corresponding tumor control probability
(TCP) calculated using Eqs. (3) and (4) for a uniform clonogen density of 109 cm3. Patients are ordered according to the physical size of the HTV.
Patient
1 fraction 3 fractions 5 fractions 8 fractions
Dpres (Gy) TCP (%) Dpres (Gy) TCP (%) Dpres (Gy) TCP (%) Dpres (Gy) TCP (%)
2 28.7 100.0 44.0 100.0 52.3 100.0 60.3 100.0
3 29.3 100.0 45.1 100.0 53.7 100.0 61.9 100.0
4 29.2 100.0 44.8 100.0 53.4 100.0 61.6 100.0
5 29.2 97.2 44.7 99.2 53.1 99.3 61.1 99.4
6 29.0 99.5 44.4 99.7 52.8 99.7 60.8 99.7
7 28.5 97.5 43.5 98.5 51.7 98.6 59.5 98.6
8 29.8 98.2 45.8 99.5 54.5 99.6 62.8 99.6
9 29.51 97.4 45.2 99.1 53.8 99.3 61.9 99.3
10 29.3 99.0 44.9 99.5 53.4 99.5 61.5 99.5
11 30.1 98.4 46.1 99.2 55.0 99.3 63.4 99.4
12 31.5 87.6 48.4 98.2 57.6 98.8 66.4 99.0
13 30.4 94.0 46.7 98.5 55.6 98.8 64.1 99.0
14 31.2 88.7 47.8 97.0 56.9 97.9 65.6 98.2
15 30.3 97.0 46.5 98.8 55.3 98.9 63.8 99.0
16 31.0 96.5 47.8 99.6 57.0 99.7 65.9 99.8
17 30.5 97.6 47.0 99.5 56.0 99.6 64.7 99.6
18 30.2 97.9 46.3 99.0 55.2 99.1 63.8 99.2
19 30.6 96.7 47.0 98.7 55.9 98.9 64.6 99.0
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TCP, as also shown for neurosurgery treatments.45 This was
particularly pronounced in the two patients (12 and 14) in
which the least favorable distributions of oxygen partial pres-
sure were found. Based on the large interpatient variability in
hypoxia observed in NSCLC10 combined with intratumor
heterogeneity in oxygenation in both time and space,11,13 it is
likely that individual patients would benefit from pretreat-
ment assessment of their particular tumor oxygenation status.
However, this is of course only valid under the assumption
that there are clinically validated methods for adapting the
treatment according to this information, and that the resulting
treatment can be safely delivered with respect to the normal
tissue toxicity and the potential motion of the tumor. The
methodology employed in the current study could represent a
promising strategy for quantitative dose prescription based
on hypoxia PET imaging.
It has to be mentioned that the conversion of PET tracer
uptake to pO2 could be associated with several uncertain-
ties. In addition to potential uncertainties related to the con-
version itself, the use of PET imaging for any quantitative
analysis requires correction for scatter and attenuation of
the annihilation photons as well as for partial volume
effects.46 For imaging of the thoracic region, correction for
respiratory motion may also be necessary.47 It should, how-
ever, be pointed out that the uncertainties discussed here
pertains to all use of PET imaging, and are not specific to
the method employed in this study. Rather, the conversion
to pO2 should be considered only after all necessary correc-
tions of the raw PET data have been performed. In patient 7,
this might not have been the case as a relatively large HTV
was observed resulting in an increase in the GTV from 6.2
to 10.7 cm3 in order to encompass the 7.8 cm3 HTV. Given
the many steps from PET imaging to prescribed dose (con-
version, segmentation, dose calculation) the accuracy of the
conversion and subsequent dose calculation should be eval-
uated with respect to its application rather than by evaluat-
ing isolated steps of the chain. The critical question is,
therefore, whether the doses calculated based on the model
are enough to achieve local control, which should be
assessed by comparing the predictions of the model with
the outcome of patients treated according to clinical praxis.
While the work presented in this paper demonstrates the
potential in quantitative hypoxia dose painting based on
radiobiological modeling, validation against clinical results
prior to translating the results and methodology to the clinic
is needed.
5. CONCLUSIONS
In this work, a radiobiological method for calculating the
prescribed dose in tumor subvolumes segmented based on
functional imaging of hypoxia was employed to investigate
the impact of fractionation on the prescribed doses calcu-
lated, taking into account the dynamic nature of the tumor
oxygenation. The importance of considering the pO2 distribu-
tion in addition to the volume for dose prescription was
demonstrated, indicating that hypoxia dose painting based on
segmentation alone may not be sufficient with respect to
achieving local control. The method resulted in prescribed
doses that were similar to the clinical practice in SBRT of
NSCLC for a range of fractions. Furthermore, the indepen-
dent calculation of tumor control probability indicated that
single-fraction SBRT could result in local control rates infe-
rior to those achievable with fractionated SBRT. Clinical vali-
dation of this (as of any radiobiological modeling approach)
is, however, required before the results of this work can be
translated to the clinic.
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